Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Rationale and design of a study to evaluate management of proteinuria in patients at high risk for vascular events: the IMPROVE trial

Journal of Human Hypertension volume 20, pages 693–700 (2006)Cite this article

Abstract

Declining kidney function predicts increasing cardiovascular risk in people with hypertension. Microalbuminuria is a marker for cardiovascular risk and declining kidney function. Agents that block the renin–angiotensin–aldosterone system (RAAS), notably angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs), reduce proteinuria and microalbuminuria, lower blood pressure and slow the progression of proteinuric kidney disease. Evidence is accumulating that the combination of an ACE inhibitor and an ARB is the optimal means of RAAS blockade in this setting, slowing the progression of nephropathy independently of blood pressure lowering to a greater degree than can be achieved using maximum approved doses of either agent alone. However, the emerging therapeutic potential of ACE inhibitor/ARB combination therapy in hypertensive kidney disease requires further characterization. The Irbesartan in the Management of PROteinuric patients at high risk for Vascular Events trial aims to determine definitively whether the combination therapy of an ARB, irbesartan and an ACE inhibitor, ramipril, is more effective than ramipril alone in reducing the urinary albumin excretion rate in patients at high cardiovascular risk with hypertension and proteinuria or microalbuminuria.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1

Similar content being viewed by others

References

  1. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY . Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004; 351: 1296–1305.

    Article  CAS  Google Scholar 

  2. Manjunath G, Tighiouart H, Ibrahim H, MacLeod B, Salem DN, Griffith JL et al. Level of kidney function as a risk factor for atherosclerotic cardiovascular outcomes in the community. J Am Coll Cardiol 2004; 41: 47–55.

    Article  Google Scholar 

  3. Anakevar NS, McMurray JJ, Velazquez EJ, Solomon SD, Kober L, Rouleau JL et al. Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. N Engl J Med 2004; 351: 1285–1295.

    Article  Google Scholar 

  4. Hall WD . Abnormalities in kidney function as a cause and a consequence of cardiovascular disease. Am J Med Sci 1999; 317: 176–182.

    Article  CAS  Google Scholar 

  5. Segura J, Ruilope LM, Zanchetti A . On the importance of estimating renal function for cardiovascular risk assessment. J Hypertens 2004; 22: 1635–1639.

    Article  CAS  Google Scholar 

  6. Ruilope LM . The kidney as a sensor of cardiovascular risk in essential hypertension. J Am Soc Nephrol 2002; 13 (suppl 3): S165–S168.

    Article  CAS  Google Scholar 

  7. Guidelines Committee. European Society of Hypertension–European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003; 21: 1011–1053.

  8. Chobanian A, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. The JNC 7 Report. JAMA 2003; 289: 2560–2572.

    Article  CAS  Google Scholar 

  9. Segura J, Campo C, Gil P, Roldan C, Vigil L, Ridicio JL et al. Development of chronic kidney disease and cardiovascular prognosis in essential hypertensive patients. J Am Soc Nephrol 2004; 15: 1616–1622.

    Article  Google Scholar 

  10. Segura J, Campo C, Ruilope LM . Effect of proteinuria and glomerular filtration rate on cardiovascular risk in essential hypertension. Kidney Int 2004; 66: S45–S49.

    Article  Google Scholar 

  11. Fesler P, Du Cailar G, Ribstein J, Mimran A . Left ventricular remodeling and renal function in never-treated essential hypertension. J Am Soc Nephrol 2003; 14: 881–887.

    Article  Google Scholar 

  12. Mann JF, Gerstein HC, Pogue J, Bosch J, Yusuf F . Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril. The HOPE randomized trial. Ann Intern Med 2001; 134: 629–636.

    Article  CAS  Google Scholar 

  13. Ibsen H, Olsen MH, Wachtell K, Borch-Johnsen K, Lindholm LH, Mogensen CE et al. Reduction in albuminuria translates to reduction in cardiovascular events in hypertensive patients: losartan intervention for endpoint reduction in hypertension study. Hypertension 2005; 45: 198–202.

    Article  CAS  Google Scholar 

  14. Jafar TH, Stark PC, Schmid CH, Landa M, Maschio G, de Jong PE et al. Progression of chronic kidney disease: the role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition: a patient-level meta-analysis. Ann Intern Med 2003; 139: 244–252.

    Article  CAS  Google Scholar 

  15. Lea J, Greene T, Hebert L, Lipkowitz M, Massry S Middleton J et al. The relationship between magnitude of proteinuria reduction and risk of end-stage renal disease: results of the African American study of kidney disease and hypertension. Arch Intern Med 2005; 165: 947–953.

    Article  Google Scholar 

  16. de Zeeuw D, Remuzzi G, Parving HH, Keane WF, Zhang Z, Shahinfar S et al. Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL. Kidney Int 2004; 65: 2309–2320.

    Article  CAS  Google Scholar 

  17. Atkins RC, Briganti EM, Lewis JB, Hunsicker LG, Braden G, Champion de Crespigny PJ et al. Proteinuria reduction and progression to renal failure in patients with type 2 diabetes mellitus and overt nephropathy. Am J Kidney Dis 2005; 45: 281–287.

    Article  Google Scholar 

  18. Kistorp C, Raymond I, Pedersen F, Gustafsson F, Faber J, Hildebrandt P . N-terminal pro-brain natriuretic peptide, C-reactive protein, and urinary albumin levels as predictors of mortality and cardiovascular events in older adults. JAMA 2005; 293: 1609–1616.

    Article  CAS  Google Scholar 

  19. Garg JP, Bakris GL . Microalbuminuria: marker of vascular dysfunction, risk factor for cardiovascular disease. Vasc Med 2002; 7: 35–43.

    Article  Google Scholar 

  20. Gerstein HC, Mann JF, Yi Q, Zinman B, Dinneen SF, Hoogwerf B et al. Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA 2001; 286: 421–426.

    Article  CAS  Google Scholar 

  21. Volpe M, Cosentino F, Ruilope LM . Is it time to measure microalbuminuria in hypertension? J Hypertens 2003; 21: 1213–1220.

    Article  CAS  Google Scholar 

  22. Parving HH, Lehnert H, Brochner-Mortensen J, Gomis R, Andersen S, Arner P et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001; 345: 870–878.

    Article  CAS  Google Scholar 

  23. Mann JF, Gerstein HC, Yi QL, Lonn EM, Hoogwerf BJ, Rashkow A et al. Development of renal disease in people at high cardiovascular risk: results of the HOPE randomized study. J Am Soc Nephrol 2003; 14: 641–647.

    Article  Google Scholar 

  24. Doulton TW, He FJ, MacGregor GA . Systematic review of combined angiotensin-converting enzyme inhibition and angiotensin receptor blockade in hypertension. Hypertension 2005; 45: 880–886.

    Article  CAS  Google Scholar 

  25. Nakao N, Yoshimura A, Morita H, Takada M, Kawahara H, Fukagawa M . Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomized controlled trial. Lancet 2003; 361: 117–124.

    Article  CAS  Google Scholar 

  26. Nakao N, Seno H, Kasuga H, Toriyama T, Kawahara H, Fukagawa M . Effects of combination treatment with losartan and trandolapril on office and ambulatory blood pressures in non-diabetic renal disease: a COOPERATE-ABP substudy. Am J Nephrol 2004; 24: 543–548.

    Article  CAS  Google Scholar 

  27. Segura J, Garcia Donaire JA, Ruilope LM . Calcium channel blockers and renal protection, insights from the latest clinical trials. J Am Soc Nephrol 2005; 16: S64–S66.

    Article  CAS  Google Scholar 

  28. Chrysant SG, Bakris GL . Amlodipine/benazepril combination therapy for hypertensive patients nonresponsive to benazepril monotherapy. Am J Hypertens 2004; 17: 590–596.

    Article  CAS  Google Scholar 

  29. Ruggenenti P, Fassi A, Ilieva AP, Bruno S, Iliev IP, Brusegan V . Preventing microalbuminuria in type 2 diabetes. N Engl J Med 2004; 351: 1941–1951.

    Article  CAS  Google Scholar 

  30. Wachtell K, Ibsen H, Olsen MH, Borch-Johnsen K, Lindholm LH, Mogensen CE et al. Albuminuria and cardiovascular risk in hypertensive patients with left ventricular hypertrophy: the LIFE study. Ann Intern Med 2003; 139: 901–906.

    Article  Google Scholar 

  31. Teo K, Yusuf S, Sleight P, Anderson C, Mookadam F, Ramos B et al., the ONTARGET/TRANSCEND investigators. Rationale, design, and baseline characteristics of two large, simple, randomized trials evaluating telmisartan, ramipril and their combination in high-risk patients. The Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial/Telmisartan Randomized Assessment Study in ACE intolerant Subjects with Cardiovascular Disease (ONTARGET/TRANSCEND) trials. Am Heart J 2004; 148: 52–61.

    Article  Google Scholar 

  32. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH . Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345: 861–869.

    Article  CAS  Google Scholar 

  33. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB . Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345: 851–860.

    Article  CAS  Google Scholar 

  34. Hunsicker LG, Atkins RC, Lewis JB, Braden G, de Crespigny PJ, DeFerrani G . Impact of irbesartan, blood pressure control, and proteinuria on renal outcomes in the Irbesartan Diabetic Nephropathy Trial. Kidney Int Suppl 2004; 92: S99–S101.

    Article  CAS  Google Scholar 

  35. Agodoa LY, Appel L, Bakris GL, Beck G, Bourgoignie J, Briggs JP . Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial. JAMA 2001; 285: 2719–2728.

    Article  CAS  Google Scholar 

  36. Wright JT Jr, Bakris G, Greene T, Agodoa LY, Appel LJ, Charleston J . Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA 2002; 288: 2421–2431.

    Article  CAS  Google Scholar 

  37. Ibsen H, Olsen MH, Wachtell K, Borch-Johnsen K, Lindholm LH, Mogensen CE . Does albuminuria predict cardiovascular outcomes on treatment with losartan versus atenolol in patients with diabetes, hypertension, and left ventricular hypertrophy? The LIFE study. Diabetes Care 2006; 29: 595–600.

    Article  CAS  Google Scholar 

  38. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G . Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000; 342: 145–153.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Preventive Medicine, Rush University Medical Center, Chicago, IL, USA

    G L Bakris

  2. Hypertension Unit, Hospital 12 de Octubre, Avenida de Córdoba s/n, Madrid, Spain

    L Ruilope

  3. Department of Nephrology and Dialysis, A. Manzoni Hospital, Lecco, Italy

    F Locatelli

  4. Bristol-Myers Squibb, Pharmaceutical Research Institute, Cardiovascular Clinical Research, Princeton, NJ, USA

    A Ptaszynska & J Dechamplain

  5. Abteilung Kardiologie und Pneumologie, Leitender Oberarzt, Universität Göttingen, Göttingen, Germany

    B Pieske

  6. Division of Medicine, Diabetes Unit, Hadassah University Hospital, Ein-Karem, Jerusalem, Israel

    I Raz

  7. Department of Cardiology, University Medical Center Groningen, Groningen, The Netherlands

    A A Voors

  8. Division of Endocrinology, Diabetes, and Hypertension, SUNY Downstate Medical Center, Brooklyn, NY, USA

    M A Weber

Authors
  1. G L Bakris
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. L Ruilope
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. F Locatelli
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. A Ptaszynska
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. B Pieske
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. I Raz
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. A A Voors
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. J Dechamplain
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. M A Weber
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bakris, G., Ruilope, L., Locatelli, F. et al. Rationale and design of a study to evaluate management of proteinuria in patients at high risk for vascular events: the IMPROVE trial. J Hum Hypertens 20, 693–700 (2006). https://doi.org/10.1038/sj.jhh.1002050

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.jhh.1002050

Keywords

This article is cited by

Search

Advanced search

Quick links